1.	GP Extended Action Triptorelin Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A-97-52014-181, 2011-004213-16, NCT01673984
2.	Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial Phase: Phase III Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: 05-8-4, NCT00243646
3.	Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000526353, CALGB-90203, NCT00430183
4.	Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
5.	Radiation Therapy With or Without Hormone Therapy in Treating Patients Who Have Undergone Surgery For Stage I, Stage II, or Stage III Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 80 and under Sponsor: Other Protocol IDs: CDR0000644215, EORTC-22043, EORTC-22043-30041, EU-20950, EUDRACT-2006-002772-17, EORTC-22043–30041, NCT00949962
6.	Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000648194, RTOG-0815, NCT00936390
7.	Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000701128, RTOG-0924, NCT01368588
8.	Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU003-10, NCT01492972
9.	A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: TAP-144-SR(6M)IP/CPH-002, U1111-1128-6861, JapicCTI-121763, NCT01546623
10.	A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TAP-144-SR(6M)IP/CPH-202, JapicCTI-121762, U1111-1128-7039, NCT01546649
11.	S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: S1216, NCT01809691
12.	Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy Phase: Phase II Type: Treatment Status: Active Age: over 21 Sponsor: Other Protocol IDs: 30296-A, L-8863, 06-2040-A-02, NCT00223665
13.	Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-190, NCT00776594
14.	Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016945, COU-AA-203, NCT01088529
15.	Neoadjuvant Ipilimumab in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0135, NCT01194271
16.	S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000696565, S1014, U10CA032102, SWOG-S1014, NCT01309672
17.	Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation Phase: Phase II Type: Treatment Status: Active Age: 9 to 40 Sponsor: NCI Protocol IDs: 110136, 11-C-0136, NCT01338987
18.	Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0378, NCT01377389
19.	The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UOSG-AMC-0803, NCT01487902
20.	Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16684, NCT01531205
21.	Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 11-211, NCT01642186
22.	Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 20 to 80 Sponsor: Other Protocol IDs: Pro00044071, NCT01717053
23.	Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Phase: Phase II Type: Supportive care Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 12-077, NCT01746849
24.	Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2012-0993, NCT01786265
25.	The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARN-509-002, NCT01790126